KANEL PHARMACEUTICALS
Pharmaceutical company · 17 brands · 19 molecules
Ranked #31 of 81 companies in Angiotensin-Ii Antagonists, Combinations
Company overview
KANEL PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 17 product registrations across 19 distinct molecules. Its portfolio is concentrated in Angiotensin-Ii Antagonists, Combinations and Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). DRAP has issued 1 alert involving its products.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Products by KANEL
1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.
Top molecules by brand count
Therapeutic classes
Regulatory record
1 alert in the DRAP feed we track.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for KANEL
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included